TXA127 (Potential)
Epidermolysis Bullosa
Pre-clinical or UndisclosedActive
Key Facts
Indication
Epidermolysis Bullosa
Phase
Pre-clinical or Undisclosed
Status
Active
Company
About Constant Therapeutics
Constant Therapeutics is a private biotech leveraging the protective and regenerative pathways of the Alternative Renin-Angiotensin System (RAS) to develop therapies for rare and severe disorders. The company's core platform involves activating the Mas and MrgD receptors to counteract the harmful effects of the classical RAS, with applications in cardiology, neurology, and dermatology. Its lead asset, TXA127, is currently in Phase 2 trials for Duchenne Muscular Dystrophy-associated cardiomyopathy and ischemic stroke recovery, positioning the company at a critical clinical inflection point. The firm operates as a lean, pre-revenue entity targeting high-value, underserved markets.
View full company profileTherapeutic Areas
Other Epidermolysis Bullosa Drugs
| Drug | Company | Phase |
|---|---|---|
| Mas/MrgD Agonist Program | Xitra Therapeutics | Pre-clinical |
| APR TD011 | APR Applied Pharma Research | Clinical Development |